BTIG raised the firm’s price target on Apogee Therapeutics (APGE) to $115 from $100 and keeps a Buy rating on the shares. The firm notes that the new EASI-75 watermark for Biologics in Atopic Dermatitis exceeded its expectations and supports a market-leading profile, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- 3 Best Stocks to Buy Now, 7/9/2025, According to Top Analysts
- Promising Phase II Results for Apogee Therapeutics’ APG777 Drive Buy Rating and $89 Price Target
- Promising Potential of Apogee Therapeutics’ APG777 in Atopic Dermatitis Market Drives Buy Rating and Increased Price Target
- Apogee Therapeutics: Promising Phase 2 Results and Future Growth Potential Justify Buy Rating
- Citi buyers of Apogee Therapeutics on weakness after APG777 data